Logo image of KYTX

KYVERNA THERAPEUTICS INC (KYTX) Stock Fundamental Analysis

NASDAQ:KYTX - Nasdaq - US5019761049 - Common Stock - Currency: USD

2.55  -0.03 (-1.16%)

After market: 2.55 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to KYTX. KYTX was compared to 560 industry peers in the Biotechnology industry. The financial health of KYTX is average, but there are quite some concerns on its profitability. KYTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KYTX has reported negative net income.
In the past year KYTX has reported a negative cash flow from operations.
KYTX Yearly Net Income VS EBIT VS OCF VS FCFKYTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

KYTX's Return On Assets of -55.79% is in line compared to the rest of the industry. KYTX outperforms 45.18% of its industry peers.
KYTX has a Return On Equity of -64.92%. This is comparable to the rest of the industry: KYTX outperforms 57.32% of its industry peers.
Industry RankSector Rank
ROA -55.79%
ROE -64.92%
ROIC N/A
ROA(3y)-51.43%
ROA(5y)N/A
ROE(3y)-75.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KYTX Yearly ROA, ROE, ROICKYTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KYTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYTX Yearly Profit, Operating, Gross MarginsKYTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, KYTX has more shares outstanding
Compared to 1 year ago, KYTX has an improved debt to assets ratio.
KYTX Yearly Shares OutstandingKYTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
KYTX Yearly Total Debt VS Total AssetsKYTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.88, we must say that KYTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.88, KYTX is in the better half of the industry, outperforming 61.07% of the companies in the same industry.
KYTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of KYTX (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.88
ROIC/WACCN/A
WACCN/A
KYTX Yearly LT Debt VS Equity VS FCFKYTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

KYTX has a Current Ratio of 7.44. This indicates that KYTX is financially healthy and has no problem in meeting its short term obligations.
KYTX has a better Current ratio (7.44) than 68.93% of its industry peers.
KYTX has a Quick Ratio of 7.44. This indicates that KYTX is financially healthy and has no problem in meeting its short term obligations.
KYTX has a Quick ratio of 7.44. This is in the better half of the industry: KYTX outperforms 69.46% of its industry peers.
Industry RankSector Rank
Current Ratio 7.44
Quick Ratio 7.44
KYTX Yearly Current Assets VS Current LiabilitesKYTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for KYTX have decreased strongly by -97.20% in the last year.
Looking at the last year, KYTX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-97.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.04%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KYTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.33% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y61.76%
EPS Next 2Y24.42%
EPS Next 3Y17.8%
EPS Next 5Y7.33%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KYTX Yearly Revenue VS EstimatesKYTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KYTX Yearly EPS VS EstimatesKYTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KYTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KYTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYTX Price Earnings VS Forward Price EarningsKYTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYTX Per share dataKYTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

KYTX's earnings are expected to grow with 17.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.42%
EPS Next 3Y17.8%

More info and screens

0

5. Dividend

5.1 Amount

KYTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KYVERNA THERAPEUTICS INC

NASDAQ:KYTX (5/28/2025, 4:52:12 PM)

After market: 2.55 0 (0%)

2.55

-0.03 (-1.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners85.13%
Inst Owner Change-9.92%
Ins Owners0.12%
Ins Owner Change0.58%
Market Cap110.21M
Analysts81.67
Price Target17.34 (580%)
Short Float %5.06%
Short Ratio8.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.17%
Min EPS beat(2)-2.95%
Max EPS beat(2)9.3%
EPS beat(4)3
Avg EPS beat(4)3.19%
Min EPS beat(4)-2.95%
Max EPS beat(4)9.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.3%
PT rev (3m)-21.3%
EPS NQ rev (1m)-2.37%
EPS NQ rev (3m)-14.49%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB 0.49
EV/EBITDA N/A
EPS(TTM)-3.38
EYN/A
EPS(NY)-3.97
Fwd EYN/A
FCF(TTM)-3.13
FCFYN/A
OCF(TTM)-3.09
OCFYN/A
SpS0
BVpS5.18
TBVpS5.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.79%
ROE -64.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.43%
ROA(5y)N/A
ROE(3y)-75.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.44
Quick Ratio 7.44
Altman-Z -0.88
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)109.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.04%
EPS Next Y61.76%
EPS Next 2Y24.42%
EPS Next 3Y17.8%
EPS Next 5Y7.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-112.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-131.4%
EBIT Next 3Y-53.39%
EBIT Next 5Y-46.38%
FCF growth 1Y-43.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.13%
OCF growth 3YN/A
OCF growth 5YN/A